Our findings proposed miR-185-5p as a novel biomarker and regulator in endometriosis pathogenesis, and these findings support the notion that target therapies against miR-185-5p should have priority in targeting PDGF and VEGF. They are therefore promising tools in therapeutic developments to control the progression and metastasis processes in endometriosis patients. This evidence concerns the gene VEGFA and endometriosis.